Page 21 - Astrazeneca

AstraZeneca manufacturing error clouds coronavirus vaccine study results

AstraZeneca and Oxford University have acknowledged a manufacturing error that is raising questions about preliminary results of their experimental Covid-19 vaccine

Explainer: When and how will Covid-19 vaccines become available?

If regulators approve any of the vaccines in coming weeks, the distribution could begin almost immediately

India Coronavirus Dispatch: AstraZeneca vaccine is key even at 70% efficacy

Why vaccines should be a public good, Keeping indoor air clean can reduce spread of SARS-CoV-2, and is favipiravir good for Covid-19?-news relevant to India's fight against the pandemic

AstraZeneca must prove it won't profit from Covid-19 vaccine: Non-govt body

The price of its candidate has been set at about $3 per dose, against at least four times more for other candidates

MARKETS: Indices end at record closing peaks; Nifty settles above 13,000

All that happened in the markets today

Affordable Covid-19 vaccines will test world's intellectual property regime

An intellectual property regime that is not flexible enough to manage the coronavirus crisis is one that will break under the weight of that techno-dystopia.

Sensex, Nifty march higher on Covid-19 vaccine progress news; ONGC rises 6%

After touching a record intra-day high of 44,271.15, Sensex ended 194.90 points or 0.44 per cent higher at 44,077.15

Euro zone business activity shrinks but Covid vaccine hopes boost optimism

The bloc's economy is on track for its first double-dip recession in nearly a decade as a second wave of the coronavirus sweeps across Europe, a Reuters poll suggested last week

How a dosing error turned into lucky punch for AstraZeneca and Oxford

"The reason we had the half-dose is serendipity," Mene Pangalos, the head of AstraZeneca's non-oncology research and development, told Reuters

Oxford-AstraZeneca vaccine shows positive results, up to 90% efficacy

Data from global trials to be submitted to the Indian regulator by the end of December

Serum Institute to focus on supplying Oxford Covid vaccine to India first

Poonawalla said the company will be able to produce 400 million doses of AstraZeneca's vaccine by July 2021 and scale up further from there

Delighted at AstraZeneca vaccine's effectiveness: Adar Poonawalla

Serum Institute of India (SII) CEO Adar Poonawalla on Monday expressed happiness at pharma major AstraZeneca's announcement that its COVID-19 vaccine candidate has been found to be 70 per cent effective on average. AstraZeneca said one dosing regimen showed vaccine efficacy of 90 per cent when the vaccine was given as a half-dose followed by a full dose at least one month apart, while another dosing regimen showed 62 per cent efficacy when given as two full doses at least one month apart. "The combined analysis from both dosing regimens resulted in an average efficacy of 70 per cent," it added. In a tweet, Poonawalla said, "I am delighted to hear that, Covishield, a low-cost, logistically manageable & soon to be widely available, #COVID19 vaccine, will offer protection up to 90% in one type of dosage regime and 62% in the other dosage regime...". SII is currently conducting clinical trials of Oxford University-AstraZeneca's COVID-19 vaccine candidate in India. AstraZeneca also ...

Astra-Oxford Covid-19 vaccine works but doses could be in short supply

Pfizer and Moderna may have an initial advantage in dealing with manufacturing challenges, as their novel messenger RNA technology can be scaled up.

Vaccine highly effective in preventing Covid-19, says AstraZeneca

AstraZeneca says late-stage trials of its Covid-19 vaccine were highly effective'' in preventing disease.

AstraZeneca will have enough Covid-19 vaccine for 200 mn doses this year

The company plans to keep the "active" drug substance in stock while it awaited regulatory approval around the world

Covid-19: AstraZeneca delivers but can't match rivals, here's what we know

The Astra-Oxford vaccine on average prevented 70% of cases in large trials in the U.K. and Brazil

India to Brazil, Astra-Oxford vaccine is key to many nations' Covid plan

The Astra vaccine costs a fraction of the price set by Pfizer; it should be easier to deploy far and wide than other shots.

Oxford-AstraZeneca Covid-19 vaccine shows immune response in older adults

The vaccine causes few side effects and provokes a response in T-cells that target the virus within 14 days of the first dose and a protective antibody response within 28 days of the booster dose

Covid-19 vaccine unlikely before early or mid-2021: WHO Southeast Asia head

Even the front-runners among vaccine companies would take at least a few months to complete Phase-III trials and evaluate the efficacy and safety of individual vaccines

Coronavirus updates: 2nd wave in Maharashtra 'soon' & the vaccine challenge

The Maharashtra government has said that the the second wave of coronavirus is expected in the state in January-February based on what is happening in Europe